Background: African Americans (AA) disproportionately develop lupus nephritis (LN) relative to European Americans and familial clustering supports causative genes. Since MYH9 underlies approximately 40% of end-stage renal disease (ESRD) in AA, we tested for genetic association with LN. Methods: Seven MYH9 single nucleotide polymorphisms (SNPs) and the E1 risk haplotype were tested for association with LN in three cohorts of AA. Results: A preliminary analysis revealed that the MYH9 E1 risk haplotype was associated with ESRD in 25 cases with presumed systemic lupus erythematosus (SLE)-associated ESRD, compared to 735 non-SLE controls (odds ratio 3.1; p = 0.010 recessive). Replication analyses were performed in 583 AA with SLE in the PROFILE cohort (318 with LN; 265 with SLE but without nephropathy) and 60 AA from the NIH (39 with LN; 21 with SLE but without nephropathy). Analysis of the NIH and larger PROFILE cohorts, as well as a combined analysis, did not support this association. Conclusions: These results suggest that AA with ESRD and coincident SLE who were recruited from dialysis clinics more likely have kidney diseases in the MYH9-associated spectrum of focal segmental glomerulosclerosis. PROFILE and NIH participants, recruited from rheumatology practices, demonstrate that MYH9 does not contribute substantially to the development of LN in AA.

Keywords:
African Americans, Genetics, Lupus nephritis, Kidney, MYH9, Systemic lupus erythematosus
1.
Kopp JB, Smith MW, Nelson GW, et al: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175–1184.
2.
Kao WH, Klag MJ, Meoni LA, et al: MYH9 is associated with non-diabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185–1192.
3.
Freedman BI, Hicks PJ, Bostrom MA, et al: Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009;75:736–745.
4.
Freedman BI, Hicks PJ, et al: Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 2009;11:3366–3371.
5.
Fessel WJ: Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med 1974;134:1027–1035.
6.
Dooley MA, Hogan S, Jennette C, Falk R: Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188–1195.
7.
Freedman BI, Wilson CH, Spray BJ, Tuttle AB, et al: Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 1997;29:729–732.
8.
Freedman BI: End-stage renal failure in African Americans: insights in kidney disease susceptibility. Nephrol Dial Transplant 2002;17:198–200.
9.
Freedman BI, Sedor JR: Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047–2051.
10.
Alarcon GS, McGwin G Jr, Petri M, et al: Baseline characteristics of a multiethnic lupus cohort: PROFILE 15. Lupus 2002;11:95–101.
11.
Wigginton JE, Cutler DJ, Abecasis GR: A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005;76:887–893.
12.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265.
13.
Tang H, Peng J, Wang P, Risch NJ: Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol 2005;28:289–301.
14.
Keene KL, Mychaleckyj JC, Smith SG, et al: Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase-1 gene with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes 2008;57:1057–1062.
15.
US Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
16.
Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR: Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000;15:1801–1807.
17.
Harley JB, Arcon-Riquelme ME, Criswell LA, et al: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204–210.
18.
Reeves-Daniel AM, Iskandar SS, Bowden DW, et al: Collapsing C1q nephropathy: another MYH9-associated kidney disease? Am J Kidney Dis 2010;55:e21–e24.
19.
Liu K, Li QZ, Gado-Vega AM, et al: Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest 2009;119:911–923.
20.
Salmon JE, Millard S, Schachter LA, et al: Fcγ RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348–1354.
21.
Alarcon GS, McGwin G Jr, Petri M, et al: Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med 2006;3:e396.
22.
Bates JS, Lessard CJ, Leon JM, et al: Meta-analysis and imputation identifies a 109-kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun 2009;10:470–477.
23.
Namjou B, Gray-McGuire C, Sestak AL, et al: Evaluation of C1q genomic region in minority racial groups of lupus. Genes Immun 2009;10:517–524.
24.
Althaus K, Greinacher A: MYH9-related platelet disorders. Semin Thromb Hemost 2009;35:189–203.
25.
Matsushita T, Hayashi H, Kunishima S, et al: Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun 2004;325:1163–1171.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.